Brand dynamics
Group Real-Time Dynamics And Cutting-Edge Information In The Field Of One Health
Jiankang Yuan wins the "Financial World Golden Wisdom Award for ESG Responsible Enterprise"
Published Time：
2020-09-16
Recently, the "Financial World Institutional Investor Forum and China Pharmaceutical and Biological Enterprise Summit (2020)", hosted by Financial World, was grandly held at the Shanghai Lunan JW Marriott Hotel. Themed "Corporate Responsibility and Long-Term Value," this grand event invited leaders from relevant departments, numerous outstanding listed companies, institutional investors, and authoritative media to participate, bringing together upstream and downstream resources of industrial development, connecting ideas and resources, and unleashing value and strength.
At the highlight of the summit—the Financial World "Golden Wisdom Award" Pharmaceutical and Biological Enterprise Value Selection Award Ceremony—Joincare Pharmaceutical Group Industry Co., Ltd. (hereinafter referred to as "Health Yuan Group") won the Financial World "Golden Wisdom Award" Pharmaceutical and Biological Industry "ESG Responsible Enterprise Award" (2020) for its outstanding performance in economic, social, environmental, and governance comprehensive value, with both market value and corporate governance receiving authoritative recognition.
It is understood that the award selection criteria are rigorous and comprehensive. The Financial World website, which established the award, was founded in 1999. It is a leading domestic financial and economic information provider jointly invested by IDG (USA) and Vertex (Singapore), and is currently one of the most influential Chinese financial websites globally. The 2020 Financial World "Golden Wisdom Award" focused on the pharmaceutical and biological industry, using consistent data mining and enhanced connectivity in breadth and depth, adhering to objective and pragmatic research, analysis, and surveys to launch this selection. This selection included awards for "ESG Responsible Enterprise," "Excellent Operation," "Top 10 Value Investments," "Scientific Research Practice," and "Commercial Value Practice." Using indicators that reflect the award requirements and highlight quality, relevant indicator data such as market performance, financial status, information disclosure system, and R&D investment were extracted, bringing together their performance in various dimensions of operation, responsibility, and innovation. Financial World's evaluation indicators were used for quantitative analysis of the information, followed by expert recommendations, voting, and netizen voting. Ultimately, Health Yuan Group stood out among numerous listed companies, further demonstrating the company's outstanding corporate governance capabilities.
In recent years, under the leadership of Chairman Zhu Baoguo, Health Yuan has developed into a comprehensive pharmaceutical group integrating R&D, production, sales, and services, and has cultivated the domestic inhalation preparation market. Multiple inhalation preparation products have been approved for listing. In addition to the key layout of the inhalation preparation platform, Health Yuan Group is also striving to build a leading domestic and world-class monoclonal antibody, sustained-release microsphere, and other biopharmaceutical and drug delivery technology platforms, laying a solid foundation for the company's future development.
It is worth mentioning that, as an important representative of China's large health industry, Health Yuan Group, which is about to celebrate its 20th anniversary of listing, has always attached importance to fulfilling its social responsibilities, regarding social responsibility as an important support for the group's soft power. Over nearly 20 years of unwavering belief, the company has integrated social responsibility management into all aspects of its strategy and governance: deeply deploying inhalation preparation products, overcoming technological barriers, and providing high-quality and safe drug options for more than 100 million asthma and chronic obstructive pulmonary disease patients in China; combining its core business advantages, and working with its holding subsidiary, Lizhu Group, to plan special public welfare projects targeting chronic disease patients, donating chronic disease drugs to impoverished hypertension, hyperlipidemia, and cardiovascular disease patients, a project that has benefited hundreds of chronic disease patient families.
By continuously exerting efforts in energy conservation and emission reduction, business model innovation, and poverty alleviation, and continuously improving its social responsibility management system, expanding the scope and level of fulfilling social responsibilities has enabled Health Yuan Group to enter a new stage of development.
Quick Navigation
+86 755-33268688 | Service Hotline
Official WeChat Official Account
Copyright © 2025 Joincare Pharmaceutical Group Industry Co., Ltd. ALL Rights Reserve.